---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-336700"
form_type: "8-K"
ticker: "CGEM"
cik: "0001789972"
company_name: "Cullinan Therapeutics, Inc."
filed_at: "2026-08-06T11:06:30+00:00"
generated_at: "2026-08-06T11:11:21.788720+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Cullinan Therapeutics Q2 2026 net loss $53.7M; cash $356M; pipeline on track

## Summary
- Net loss $53.7M vs $70.1M YoY; R&D expenses $44.4M vs $61.0M; G&A $12.8M vs $14.8M.
- Cash and investments $356M as of June 30, 2026; runway into 2029.
- CLN-049 Phase 2 in R/R AML to start Q3 2026 after positive FDA End-of-Phase 1 meeting.
- CLN-978 multi-dose data in RA Q3 2026, SLE Q4 2026; Phase 2 expansion early 2027.
- Zipalertinib NDA accepted; PDUFA Feb 27, 2027; Cullinan eligible for $30M on 2L approval.

## SEC filing metadata
- accession: 0001193125-26-336700
- form_type: 8-K
- ticker: CGEM
- cik: 0001789972
- company_name: Cullinan Therapeutics, Inc.
- filed_at: 2026-08-06T11:06:30+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1789972/000119312526336700/0001193125-26-336700-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1789972/000119312526336700/cgem-20260806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-336700
- JSON: https://secwatch.observer/filing/0001193125-26-336700.json
- Plain text: https://secwatch.observer/filing/0001193125-26-336700.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.